From the Division of Anesthesiology Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Division of Pulmonary and Critical Care Medicine and Center for Health Services Research, Vanderbilt University School of Medicine.
Anesth Analg. 2018 Sep;127(3):690-697. doi: 10.1213/ANE.0000000000003358.
Persistent pain likely interferes with quality of life in survivors of critical illness, but data are limited on its prevalence and risk factors. We sought to determine the prevalence of persistent pain after critical illness and its interference with daily life. Additionally, we sought to determine if intensive care unit (ICU) opioid exposure is a risk factor for its development.
In a cohort of adult medical and surgical ICU survivors, we used the brief pain inventory (BPI) to assess pain intensity and pain interference of daily life at 3 and 12 months after hospital discharge. We used proportional odds logistic regression with Bonferroni correction to evaluate the independent association of ICU opioid exposure with BPI scores, adjusting for potential confounders including age, preadmission opioid use, frailty, surgery, severity of illness, and durations of delirium and sepsis while in the ICU.
We obtained BPI outcomes in 295 patients overall. At 3 and 12 months, 77% and 74% of patients reported persistent pain symptoms, respectively. The median (interquartile range) pain intensity score was 3 (1, 5) at both 3 and 12 months. Pain interference with daily life was reported in 59% and 62% of patients at 3 and 12 months, respectively. The median overall pain interference score was 2 (0, 5) at both 3 and 12 months. ICU opioid exposure was not associated with increased pain intensity at 3 months (odds ratio [OR; 95% confidence interval], 2.12 [0.92-4.93]; P = .18) or 12 months (OR, 2.58 [1.26-5.29]; P = .04). ICU opioid exposure was not associated with increased pain interference of daily life at 3 months (OR, 1.48 [0.65-3.38]; P = .64) or 12 months (OR, 1.46 [0.72-2.96]; P = .58).
Persistent pain is prevalent after critical illness and frequently interferes with daily life. Increased ICU opioid exposure was not associated with worse pain symptoms. Further studies are needed to identify modifiable risk factors for persistent pain in the critically ill and the effects of ICU opioids on patients with and without chronic pain.
持续性疼痛可能会影响危重病幸存者的生活质量,但有关其患病率和危险因素的数据有限。我们旨在确定危重病后持续性疼痛的患病率及其对日常生活的干扰程度。此外,我们还试图确定重症监护病房(ICU)阿片类药物暴露是否是其发展的危险因素。
在一项成年内科和外科 ICU 幸存者队列研究中,我们使用简短疼痛量表(BPI)在出院后 3 个月和 12 个月评估疼痛强度和日常生活的疼痛干扰。我们使用具有 Bonferroni 校正的比例优势逻辑回归来评估 ICU 阿片类药物暴露与 BPI 评分之间的独立关联,调整了年龄、入院前阿片类药物使用、脆弱性、手术、疾病严重程度以及 ICU 中谵妄和脓毒症持续时间等潜在混杂因素。
我们总共获得了 295 名患者的 BPI 结果。在 3 个月和 12 个月时,分别有 77%和 74%的患者报告有持续性疼痛症状。疼痛强度评分中位数(四分位距)分别为 3(1,5)在 3 个月和 12 个月时。分别有 59%和 62%的患者在 3 个月和 12 个月时报告日常生活中的疼痛干扰。疼痛总干扰评分中位数分别为 2(0,5)在 3 个月和 12 个月时。ICU 阿片类药物暴露与 3 个月时的疼痛强度增加无关(比值比[OR];95%置信区间],2.12[0.92-4.93];P =.18)或 12 个月时(OR,2.58[1.26-5.29];P =.04)。ICU 阿片类药物暴露与 3 个月时日常生活中的疼痛干扰增加无关(OR,1.48[0.65-3.38];P =.64)或 12 个月时(OR,1.46[0.72-2.96];P =.58)。
危重病后持续性疼痛很常见,并且经常会干扰日常生活。ICU 阿片类药物暴露的增加与更严重的疼痛症状无关。需要进一步研究以确定危重病患者中持续性疼痛的可改变危险因素,以及 ICU 阿片类药物对有和无慢性疼痛患者的影响。